Key clinical point: A new 17-gene signature may help identify patients with chronic lymphocytic leukemia (CLL) who are likely to achieve long-term remission with frontline FCR chemoimmunotherapy.
Major finding: Among patients with IGHV-unmutated CLL, those with signature-defined unfavorable prognosis were more likely to experience progression after frontline FCR chemoimmunotherapy (HR, 3.83 in discovery/training cohort, and 1.90 in validation cohort).
Study details: Retrospective dual cohort study among 210 treatment-naive adults with CLL who received frontline FCR chemoimmunotherapy.
Disclosures: Dr. Herling reported financial disclosures related to Hoffmann-La Roche, and Dr. Coombes reported grants from the National Institutes of Health. The study was funded by the Chronic Lymphocytic Leukaemia Global Research Foundation and the National Institutes of Health/National Cancer Institute.
Herling CD et al. Lancet Oncol. 2019;20:1576-86.